Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P642: Anxiety and depression: beyond simple consequences of chronic inflammatory bowel diseases

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Timofte*1, E. Gologan1, A. S. Leca2, G-E. Galca-Blanariu1,2, G. Stefanescu1,2

1‘Gr.T Popa’ Medicine and Pharmacy University, Medical Semiology and Gastroenterology, Iasi, Romania, 2Institute of Gastroenterology and Hepatology, Iasi, Romania

P643: Effectiveness of enhanced recovery after surgery in IBD: a propensity score matched cohort study in a single Italian centre

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Mineccia1, M. Daperno*2, P. Massucco1, F. Menonna1, V. Gentile1, P. Germani1, M. Mendolaro2, R. Rocca2, A. Ferrero1

1Mauriziano Hospital, Surgery, Turin, Italy, 2Mauriziano Hospital, Gastroenterology Unit, Torino, Italy

P644: Mindfulness-based stress reduction in adult patients with active Crohn's disease: preliminary findings based on the subjective units of distress scale: an IIRN study

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Schwartz*1, G. Goren2, P. Perpinial2, M. Friger3, O. Sarid2, V. Slonim-Nevo2, R. Sergienko3, A. Nemirovsky4, E. Vinogradov4, D. Greenberg6, A. Monsonego4, D. Turner7, A. Eliakim8, S. Ben Horin8, Y. Chowers9, H. Yanai10, I. Dotan10, S. Odes1

1Soroka Medical Center, Gastroenterology, Beer Sheva, Israel, 2Ben-Gurion University of the Negev, Social Work, Beer Sheva, Israel, 3Ben-Gurion University of the Negev, Public Health, Beer Sheva, Israel, 4Ben-Gurion University of the Negev, Microbiology, Immunology and Genetics, Beer Sheva, Israel, 6Ben-Gurion University of the Negev, Health Systems Management, Beer Sheva, Israel, 7Shaare Zedek Medical Center, Gastroenterology, Jerusalem, Israel, 8Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 9Rambam Health Care Campus, Gastroenterology, Haifa, Israel, 10Rabin Medical Center, Gastroenterology, Petach Tikva, Israel

P645: Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Guardiola*1,2, L. Rodriguez Alonso1, N. Padullés3, E. Santacana3, K. Serra1, A. Padulles3, A. Ruiz-Cerulla1, P. Gilabert1, C. Arajol1, G. Ibañez-Sanz1, B. Camps1, H. Colom2, J. Bas4, F. Morandeira4, E. Sanchez1, J. Orobitg1, F. Rodriguez Moranta1

1Hospital Universitari de Bellvitge, Gastroenterology, L’Hospitalet de Llobregat, Spain, 2Universitat de Barcelona, Barcelona, Spain, 3Hospital Universitari de Bellvitge, Pharmacy, L’Hospitalet de Llobregat, Spain, 4Hospital Universitari de Bellvitge, Immunology, L’Hospitalet de Llobregat, Spain

P646: Histological remission in patients with moderate-to-severe ulcerative colitis undergoing biological therapy: a single-centre experience

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Di Ruscio*1, A. Variola1, A. Geccherle1, G. Lunardi2, P. Castelli3, G. Zamboni3, R. Riddell4

1IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar, Italy, 2IRCCS Sacro Cuore Don Calabria, Division of Medical Oncology, Negrar, Italy, 3IRCCS Sacro Cuore Don Calabria, Department of Pathology, Negrar, Italy, 4Mount Sinai Hospital University of Toronto, Department of Pathology and Laboratory Medicine, Toronto, Canada

P647: A pilot study: The importance of cognitive flexibility and flexibility in coping with stress for the quality of life in inflammatory bowel disease patients during biological therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Rudnik*1,2, G. Piotrowicz2, M. Basińska3, G. Rydzewska4,5, V. Rashedi6,7

1University of Gdansk, Institute of Psychology, Gdansk, Poland, 2Independent Public Health Care of the Ministry of the Internal Affairs, Department of Gastroenterology, Gdansk, Poland, 3Kazimierz Wielki University, Department of Clinical Psychology, Bydgoszcz, Poland, 4Central Clinical Hospital of the Ministry of Interior and Administration, Department of Gastroenterology, Warsaw, Poland, 5Jan Kochanowski University, The Faculty of Medicine and Health Sciences, Kielce, Poland, 6Iran University of Medical Sciences, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Tehran, Iran, Islamic Republic of, 7University of Social Welfare and Rehabilitation Sciences, Iranian Research Centre on Aging, Tehran, Iran, Islamic Republic of

P648: Anti-TNF-α therapy, use of corticosteroids, and colectomy among paediatric and adolescent patients with ulcerative colitis: a nationwide study

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Lund*1,2, M. D. Larsen1, T. Knudsen3,4, J. Kjeldsen5,6, R. G. Nielsen7,8, B. M. Noergaard1,2

1Odense University Hospital, Center for Clinical Epidemiology, Odense, Denmark, 2University of Southern Denmark, Department of Clinical Research, Research unit of Clinical Epidemiology, Odense, Denmark, 3Hospital of Southwest Jutland, Department of Medicine, Esbjerg, Denmark, 4University of Southern Denmark, Institute for Regional Health Science, Center Southwest Jutland, Esbjerg, Denmark, 5Odense University Hospital, Department of Medical Gastroenterology S, Odense, Denmark, 6University of Southern Denmark, Department of Clinical Research, Research unit of Medical Gastroenterology, Odense, Denmark, 7Odense University Hospital, Hans Christian Andersen Children's Hospital, Odense, Denmark, 8University of Southern Denmark, Department of Clinical Research, Research unit of Pediatrics, Odense, Denmark

P649: Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Visuri*1, C. Eriksson1, E. Mårdberg1, O. Grip2, A. Gustavsson3, H. Hjortswang4,5, P. Karling6, S. Montgomery7,8,9, P. Myrelid4,10, O. Olén9,11,12, The SWIBREG Study Group1, J. F. Ludvigsson13,14, J. Halfvarson1

1Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 2Skåne University Hospital, Department of Gastroenterology, Malmö, Sweden, 3Central Hospital, Department of Internal Medicine, Karlstad, Sweden, 4Linköping University, Department of Clinical and Experimental Medicine, Linköping, Sweden, 5Linköping University, Department of Gastroenterology, Linköping, Sweden, 6Umeå University, Department of Public Health and Clinical Medicine, Umeå, Sweden, 7Örebro University, Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro, Sweden, 8University College London, Department of Epidemiology and Public Health, London, UK, 9Karolinska Institutet, Clinical Epidemiology Unit, Department of Medicine Solna, Stockholm, Sweden, 10Linköping University Hospital, Department of Surgery, Linköping, Sweden, 11Stockholm South General Hospital, Sachs’ Children and Youth Hospital, Stockholm, Sweden, 12Karolinska Institutet, Department of Clinical Science and Education Södersjukhuset, Stockholm, Sweden, 13Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 14Örebro University Hospital, Department of Pediatrics, Örebro, Sweden

P650: Mechanisms of Infliximab failure: the predictive role of MMP3

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Barberio*1, R. D'Incà2, S. Facchin3, M. Dalla Gasperina1, C. Fohom1, R. Cardin1, E. Savarino2, F. Zingone1

1Dr., Gastroenterology, Padova, Italy, 2University of Padua, Department of Oncological Gastrointestinal Surgery, Padova, Italy, 3University of Padua, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, Padova, Italy

P651: Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Winter*1, J. Izanec2, C. Busse2, Y. Wang3, J. Hyams4

1MassGeneral Hospital for Children, Boston, USA, 2Janssen Scientific Affairs, LLC, Horsham, USA, 3Janssen Research & Development, LLC, Spring House, USA, 4Connecticut Children’s Medical Center, Hartford, USA

P652: Compare risk factors associated with infectious complication in Crohn’s disease with and without preoperative infliximab

ECCO '19 Copenhagen

Year: 2019
Authors:

X. Ge*1, Q. Cao2, W. Zhou1

1Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, General Surgery, Hangzhou, China, 2Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Department of Gastroenterology, Hangzhou, China

P653: Ligation of the intersphincteric fistula tract vs. endorectal advancement flap for high perianal fistulas in Crohn’s disease: a retrospective cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

E. van Praag*1, M. Stellingwerf1, J. van der Bilt1, K. Gecse2, W. Bemelman1, C. Buskens1

1Amsterdam UMC, Surgery, Amsterdam, The Netherlands, 2Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands

P654: Monitoring of drug concentrations to predict remission under ustekinumab induction therapy in Crohn's disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Soufflet1, G. Boschetti1, X. Roblin3, C. Cuerq1,4, N. Williet3, R. Duclaux Loras5, P. Danion1, A. Mialon4, S. Paul6, B. Flourié1, S. Nancey*1

1Hospices Civils de Lyon, Gastroenterology, PIERRE BENITE, France, 3CHU Saint Etienne, Gastroenterology, Saint Etienne, France, 4Hospices Civils de Lyon, Biochemistry, Pierre Benite, France, 5Hospices Civils de Lyon, Gastroenterology Paediatry, Bron, France, 6CHU Saint Etienne, GIMAP, Saint Etienne, France

P655: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Facchin*1, N. Vitulo2, B. Perini1, A. Buda3, F. Zingone4, C. Romualdi5, R. D'Incà4, E. Savarino4

1University of Padua, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, Padova, Italy, 2University of Padua, Department of Biotechnology, Verona, Italy, 3S.Maria del Prato Hospital, Department of Oncological Gastrointestinal Surgery, Feltre( BL), Italy, 4University of Padua, Department of Oncological Gastrointestinal Surgery, Padova, Italy, 5University of Padua, Department of Biology, Padova, Italy

P656: Malnutrition rates are highest in pre-surgical Crohn’s disease when compared with active CD, CD in remission and UC in remission

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Sandall*1,2, K. Patel3, P. Shah2, D. O'Hanlon2, S. Smith1, A. Darakhshan4, P. Irving5, J. Sanderson5, M. Lomer1,2

1King's College London, Nutritional Sciences Division, London, UK, 2Guy's and St Thomas' NHS Foundation Trust, Nutrition and Dietetics, London, UK, 3St George’s Hospital NHS Foundation Trust, Gastroenterology, London, UK, 4Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, UK, 5Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, UK

P657: Backwash ileitis not influences the risk of the pouchitis, but can increase the risk of the pouch dysplasia

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Banasiewicz*1, J. Paszkowski1

1University of Medical Sciences, General, Endocrynological Surgery and Gastrointestinal Oncology, Poznań, Poland

P658: Efficacy and safety of thalidomide in adults with refractory Crohn’s disease to maintain clinical remission: a retrospective cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Lin*1, Z. Huang1, K. Chao1, X. Gao1

1The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

P659: Efficacy of switching from infliximab to golimumab in ulcerative colitis patients on deep remission

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Viazis*1, C. Pontas1, M. Gazouli2, T. Tsigaridas1, I. Tziortziotis1, C. Chatzievangelinou1, F. Gkeros1, M. Vraka1, A. Tsatsa1, E. Tsoukali1, M. Galanopoulos1, G. J. Mantzaris1

1Evangelismos Hospital, Gastroenterology Department, Athens, Greece, 2Medical School, National and Kapodistrian University of Athens, Department of Molecular Biology, Athens, Greece

P660: Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Flanagan*1, P. R. Gibson2, A. Ross1, O. Rosella3, S. J. Bell1

1St Vincent's Hospital, Gastroenterology, Melbourne, Australia, 2Alfred Health, Gastroenterology, Melbourne, Australia, 3Monash University Central Clinical School, Melbourne, Australia

P661: Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial

ECCO '19 Copenhagen

Year: 2019
Authors:

B. G. Feagan*1, G. D'Haens2, K. Usiskin3, J. Liu3, D. Paul3, R. K. Pai4

1Robarts Clinical Trials, Western University, London, Canada, 2Academic Medical Center, Amsterdam, The Netherlands, 3Celgene Corporation, Summit, USA, 4Mayo Clinic, Scottsdale, USA